MediciNova Announces Exploratory Interim Clinical Outcomes Data from...

MediciNova Announces Exploratory Interim Clinical Outcomes Data from...


MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, today presented exploratory interim data from MediciNova's ongoing clinical trial of MN-166 in amyotrophic lateral sclerosis at the American Academy of Neurology 69th Annual Meeting in Boston. The exploratory interim analysis of survival rate was conducted on 47 randomized ALS patients without non-invasive ventilator support who completed per-protocol treatment vs. subjects who withdrew from the study before the open-label period .



from Biotech News